eIFU and
Document Library

Ms. Steyn has extensive experience in senior accounting, commercial and financial analysis, and audit roles across listed and private companies. She joined OncoSil from Flynn Group ANZ, a division of Flynn Group LP, a multibillion-dollar franchise operator in the United States. Her background includes financial and commercial roles at Sirtex Medical (ASX: SRX), a former ASX 200 radiopharmaceutical medical device company, as well as Deloitte Touche Tohmatsu and Grant Thornton. She holds a Bachelor of Commerce and a Postgraduate Diploma in Accounting and is a Chartered Accountant (CA) charter holder.

Lel Smits is an award-winning entrepreneur, director and leader with a significant track record advising more than 500 ASX-listed management teams and Boards and serving as a Director on Australian Shareholders’ Association since 2021. Lel was awarded Director of the Year by Women in Finance in 2024 and 2022.

Commencing her career as a journalist, Lel gained extensive global financial markets experience through producing and presenting thousands of finance reports and CEO interviews as a broadcast finance journalist in Australia and as a New York foreign correspondent for the Australian Financial Review, reporting from Wall Street, U.S.A.

Extensive ASX listed company experience and formal education foundations propelled Lel to advise and contribute to more entrepreneurial ventures and boards through governance, strategy and risk oversight and marketing, brand, communications and corporate affairs oversight in the investment community.

Lel is a graduate of Australian Institute of Company Directors’ (AICD) Company Directors Course, has secured a Diploma of Investor Relations from Australasian Investor Relations Association (AIRA) and a Master of Arts in Journalism from University of Technology, Sydney (UTS).

Professor Jon Bell is a Manchester Academic Health Science Centre (MAHSC) Honorary Clinical Professor at The University of Manchester. He trained in surgery and clinical radiology before completing higher sub-specialty training in Interventional Radiology. He is an internationally recognised expert in Interventional Oncology with a primary interest in minimally invasive liver directed therapies.

Jon is a member of the Interventional Procedures Advisory Committee at the National Institute for Health and Care Excellence and former chair of the Patient Safety and Quality Committee of the British Society of Interventional Radiology. He was awarded Fellowship of the Cardiovascular and Interventional Radiological Society of Europe in 2019.

Christian has extensive experience with listed and private companies includes corporate secretarial, accounting and general management through The CFO Solution and previous roles. The CFO Solution has over 20 years’ expertise working with listed life science companies.

Nigel Lange is the Chief Executive Officer, Managing Director and President of EMEA for OncoSil Medical. Nigel has over 35 years’ experience in the medical device and pharmaceutical industries, with over 20 years’ experience in brachytherapy. Nigel is also a specialist in corporate turnaround.

Nigel assumed the role of CEO and MD for OncoSil Medical in January 2021. Prior to his role as CEO, he was appointed President of EMEA in May 2020 with responsibility for EMEA business development and commercialisation and he continues to serve in this role.

Previously, Nigel served as Chief Executive Officer at Sirtex Medical where he was responsible for the global business development and engineered a restructure of the company which resulted in the realisation of a cost saving of $45 million.

In his 16-year career at Sirtex, Nigel has held several executive roles across different regions globally while focusing on business leadership, corporate development, strategic licensing agreements with third parties, mergers and acquisitions and sales management. Nigel established the European division of Sirtex, where the technology had become a prominent treatment for liver cancer in over 300 centres across EMEA and achieved market penetration in all major EU markets.

Prior to Sirtex, Nigel started his extensive career in brachytherapy at MDS Nordion in 1999 in the targeted therapies division and has continued to grow his expertise over the following years.

Nigel received his Bachelor of Arts from York University, Ontario in 1980 and followed on with a Bachelor of Commerce from the University of Windsor, Ontario where he graduated in 1984.

Nicole Wilson is the Vice President of Regulatory Affairs and Quality at OncoSil Medical, with over 15 years’ experience in industry. In this role, Nicole oversees global strategic alignment to support the business growth through the overall development, implementation, maintenance, compliance, and execution of strategies ensuring that approaches are innovative, industry-leading, and meeting the needs of customers and the business from a Quality and Regulatory perspective.

Prior to joining OncoSil, Nicole was a Global Regulatory Affairs Manager at Sirtex Medical, focusing on preparation and maintenance of international product registrations for their brachytherapy device.

Nicole has a science degree majoring in physics.

David Turner is the Global Head of Medical Affairs for OncoSil Medical. He is responsible for bridging relationships between the oncology community and the research and commercial sides of the business, as well as analysis of clinical studies, and development of the publications plan.

An immunologist by training, David brings over 40 years’ experience in healthcare, working both within the pharmaceutical, medical device, diagnostics, and health technology industries, as well as at a senior level in healthcare consulting.  He has spent the past 30 years in scientific affairs and marketing with a significant emphasis on oncology. 

David has over 25 years at board and senior executive level, most recently as Global Head of Marketing for Sirtex Medical Limited.  He previously contributed substantially to the growth of two international healthcare marketing communication consultancies from start up to the largest practices in their sectors, as well as the leading oncology patient information and chemotherapy prescribing system.  David also directed a patient advocacy campaign which successfully lobbied the UK government to substantially increase funding for oncology drugs and services in the NHS.

Henk Tissing is the Director of Global Clinical Affairs at OncoSil Medical. He is responsible for leading the clinical research program on novel provide global clinical evidence for the company.

Henk comes with over 25 years’ experience in the medical device and pharmaceutical industry specializing in the development and management of national and international clinical studies. More specifically, Henk has held senior leadership positions in the development of clinical programs for brachytherapy over the past 10 years.

Prior to joining OncoSil, Henk held the position of Vice President, Clinical Development Interventional Oncology for BTG (Now acquired by Boston Scientific) responsible for the clinical development program for SIRT, Bland/Drug-eluting Beads and Cryoablation products and prior to that, was the Director of Clinical Affairs, EMEA for SIRTEX Medical, responsible for the planning and execution of the Clinical Research Program in the EMEA region.

Henk graduated with his degree in Biomedical Sciences at the Leiden State University, faculty of Medicine, Leiden, The Netherlands in 1991.

Mr Leedman is a marketing and investor relations professional with over 15 years’ experience in the biotechnology industry. Mr Leedman is the founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Limited to form ResApp Health Limited where Mr Leedman is the Executive Director of Corporate Affairs. ResApp Health is currently under a Scheme of Arrangement to be acquired by Pfizer (Aust) Limited.

Mr Leedman is an experienced public company director having formerly been the Chairman of Neurotech International Limited, Nutritional Growth Solutions Limited, Neuroscientific Biopharmaceuticals Limited and was a Director of Alcidion Corporation Limited.

Prior to ResApp, Mr Leedman co-founded OncoSil Medical Limited and Biolife Science (QLD) Limited (acquired by Imugene Limited). Mr Leedman previously served for ten years as Vice President, Investor Relations for pSivida Corp. Limited, which was listed on the ASX, Frankfurt and NASDAQ. He was formerly the WA Chairman of AusBiotech, the association of biotechnology companies in Australia. Mr Leedman holds a Bachelor of Economics and a Master of Business Administration from the University of Western Australia.

Mr Cubbin is an experienced biopharmaceutical executive with over 30 years’ experience in senior executive, CFO, Director and Chair roles, across varied industries.

During his tenure as Group Chief Financial Officer at Telix Pharmaceuticals Limited (ASX:TLX), he was a key member of the team which successfully completed the IPO, raised $270 million in capital and grew the business to a multi‐billion dollar market capitalisation. Mr Cubbin has also served as Chairman of various boards, including Australian Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine.

Dr Liberatore is an experienced biopharmaceutical executive with over 25 years’ experience in senior Business Development, R&D and strategic operational management positions including taking products to market. Until recently, he was the Group Chief Operating Officer at Telix Pharmaceuticals (ASX:TLX) a global biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals.

Currently, Dr Liberatore is a Strategic Advisor to GlyTherix Ltd, an Australian immuno-oncology company specializing in developing antibody radiopharmaceuticals for solid tumours. Gabriel holds a PhD in Neuroscience from the University of Melbourne, post-doctoral research fellowship from Columbia University (New York) an MBA (Corporate Strategy) from La-Trobe University and has completed the Australian Institute of Company Directors course.

B.SC (Hons) and Ph.D. (Aberdeen) FAICD

Dr Cross is a highly regarded pharmaceutical executive with over 30 years’ experience including corporate and industry leadership roles directly influencing healthcare policy and government legislation in Australia and global business management, marketing and sales roles.

From 2013 to 2015, Dr Cross was Chairman of Medicines Australia, the country’s peak body representing the research based pharmaceutical industry in Australia. Prior to leading Medicines Australia, from 2010 to 2013 Dr Cross was Chairman of both the Generics Medicine Industry Association and Pharmaceutical Industry Council. During this time, Dr Cross was also Managing Director of Alphapharm in Australia and New Zealand, with responsibility for 750 employees and sales of over US $500m per annum.

From 2003 to 2008, Dr Cross was Country Head and Managing Director of Novartis Australia and New Zealand, and Head of Global Marketing and Sales Capabilities from 2001 to 2003, based in Switzerland.

David James is the Head of Manufacturing and Operations as well as the Radiation Safety Officer at OncoSil Medical. He is responsible for the performance and integration of all aspects of the company’s operations including Manufacturing, Supply Chain, Supply Management, Customer Service, Product R&D, Operational Excellence and Operations Quality. David joined OncoSil Medical in 2015 and comes with over 25 years’ experience in this field.

Prior to joining OncoSil, David ran his own consulting firm specialising in the medical device, veterinary medicines and pharmaceutical industry specializing in production, supply chain, production site set-up, product formulation and pharmaceutical processing skills.

Previously, David was the Global Operations Manager at Sirtex Medical where he was responsible for managing the global operations team which includes production, supply chain, customer service and engineering.  He also had the responsibility for the design, construction, and commissioning of Sirtex’s first in-house manufacturing plant in Wilmington DC, USA.

David has a master’s in Business and Technology from the University of New South Wales, and a Bachelor of Science from the University of Newcastle. David is a Chartered Chemist with the Royal Australian Chemical Institute.

Dr Cross is a highly regarded pharmaceutical executive with over 30 years’ experience including corporate and industry leadership roles directly influencing healthcare policy and government legislation in Australia and global business management, marketing and sales roles.

From 2013 to 2015, Dr Cross was Chairman of Medicines Australia, the country’s peak body representing the research based pharmaceutical industry in Australia. Prior to leading Medicines Australia, from 2010 to 2013 Dr Cross was Chairman of both the Generics Medicine Industry Association and Pharmaceutical Industry Council. During this time, Dr Cross was also Managing Director of Alphapharm in Australia and New Zealand, with responsibility for 750 employees and sales of over US $500m per annum.

From 2003 to 2008, Dr Cross was Country Head and Managing Director of Novartis Australia and New Zealand, and Head of Global Marketing and Sales Capabilities from 2001 to 2003, based in Switzerland.

Renzo DiCarlo is the Head of Transformation for OncoSil Medical and offers extensive international experience; having lived in North America and Europe with business dealings in Asia and Africa. He is responsible for the performance and integration of all aspects of the company’s Product R&D.

A proven nuclear medicine executive Renzo brings over twenty-five years’ experience in therapeutic drugs and medical devices. Renzo has inspired teams to innovate and deliver first-in world FDA, EMEA, and TGA approved therapeutic drugs and medical devices in the radiotherapeutic and nuclear diagnostic fields. He led the R&D of TheraSphere and established the first PET production technology with the University of Liege. In addition, Renzo led the development and set-up of the very first Lu-177, Y-90 and Sr-82 isotopes radiochemical processes in the industry in the early 2000s.